The Different Molecular Code in Generation of Dopaminergic Neurons from Astrocytes and Mesenchymal Stem Cells
Abstract
:1. Introduction
2. Results
2.1. Characterization of AS and MSCs Primary Culture
2.2. AS but Not MSCs Were Efficiently Inducted into DA Neurons by Transcriptional Regulation
2.3. Higher Neuronal Plasticity of AS Compared with MSCs by Chemical Modulation
2.4. The Different Role of Morphogens SHH, FGF8, and FGF2 in Induction MSCs and AS into Dopaminergic Neuron-like Cells
2.5. Enhanced Induction Efficiency and Maturation of DA Neurons by the Combination of Transcriptional and Chemical Regulation
2.6. The Role of Transcription Factors and Morphogens in the Induction into DA Identity from AS and MSCs
3. Discussion
4. Materials and Methods
4.1. Plasmid Construction and Viral Production
4.2. The Primary Culture of AS, AD-MSCs and UC-MSCs
4.3. Flow Cytometry Analysis
4.4. Immunofluorescence
4.5. Cell Quantification
4.6. Western Blot
4.7. RT-PCR
4.8. Transcriptional Factors-Based Neuron Induction
4.9. Chemicals and Morphogens Induction
4.10. Statistical Analysis
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Pires, A.O.; Teixeira, F.G.; Mendes-Pinheiro, B.; Serra, S.C.; Sousa, N.; Salgado, A.J. Old and new challenges in Parkinson’s disease therapeutics. Prog. Neurobiol. 2017, 156, 69–89. [Google Scholar] [CrossRef] [PubMed]
- Cacabelos, R. Parkinson’s Disease: From Pathogenesis to Pharmacogenomics. Int. J. Mol. Sci. 2017, 18, 551. [Google Scholar] [CrossRef]
- Barker, R.A.; Drouin-Ouellet, J.; Parmar, M. Cell-based therapies for Parkinson disease-past insights and future potential. Nat. Rev. Neurol. 2015, 11, 492–503. [Google Scholar] [CrossRef]
- Freed, W.J.; Perlow, M.J.; Karoum, F.; Seiger, A.; Olson, L.; Hoffer, B.J.; Wyatt, R.J. Restoration of Dopaminergic Function by Grafbng of Fetal Rat Substantia Nigra to the Caudate Nucleus: Long-Term Behavioral, Biochemical, and Histochemical Studies. Ann. Neurol. 1980, 8, 510–519. [Google Scholar] [CrossRef]
- Liu, Z.; Cheung, H.H. Stem Cell-Based Therapies for Parkinson Disease. Int. J. Mol. Sci. 2020, 21, 8060. [Google Scholar] [CrossRef]
- Yang, D.; Zhang, Z.J.; Oldenburg, M.; Ayala, M.; Zhang, S.C. Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats. Stem Cells 2008, 26, 55–63. [Google Scholar] [CrossRef]
- Garitaonandia, I.; Gonzalez, R.; Christiansen-Weber, T.; Abramihina, T.; Poustovoitov, M.; Noskov, A.; Sherman, G.; Semechkin, A.; Snyder, E.; Kern, R. Neural Stem Cell Tumorigenicity and Biodistribution Assessment for Phase I Clinical Trial in Parkinson’s Disease. Sci. Rep. 2016, 6, 34478. [Google Scholar] [CrossRef] [Green Version]
- Hallett, P.J.; Deleidi, M.; Astradsson, A.; Smith, G.A.; Cooper, O.; Osborn, T.M.; Sundberg, M.; Moore, M.A.; Perez-Torres, E.; Brownell, A.L.; et al. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson’s disease. Cell Stem Cell 2015, 16, 269–274. [Google Scholar] [CrossRef] [Green Version]
- Lee, A.S.; Tang, C.; Rao, M.S.; Weissman, I.L.; Wu, J.C. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat. Med. 2013, 19, 998–1004. [Google Scholar] [CrossRef] [Green Version]
- Teixeira, F.G.; Carvalho, M.M.; Sousa, N.; Salgado, A.J. Mesenchymal stem cells secretome: A new paradigm for central nervous system regeneration? Cell. Mol. Life Sci. 2013, 70, 3871–3882. [Google Scholar] [CrossRef]
- Borkowska, P.; Zielinska, A.; Paul-Samojedny, M.; Stojko, R.; Kowalski, J. Synergistic Effect of the Long-Term Overexpression of Bcl-2 and BDNF Lentiviral in Cell Protecting against Death and Generating TH Positive and CHAT Positive Cells from MSC. Int. J. Mol. Sci. 2021, 22, 7086. [Google Scholar] [CrossRef]
- Blandini, F.; Cova, L.; Armentero, M.T.; Zennaro, E.; Levandis, G.; Bossolasco, P.; Calzarossa, C.; Mellone, M.; Giuseppe, B.; Deliliers, G.L.; et al. Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. Cell Transpl. 2010, 19, 203–217. [Google Scholar] [CrossRef]
- Venkatesh, K.; Sen, D. Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson’s Disease. Curr. Stem Cell Res. Ther. 2017, 12, 326–347. [Google Scholar] [CrossRef] [PubMed]
- Tomov, N. Glial cells in intracerebral transplantation for Parkinson’s disease. Neural Regen. Res. 2020, 15, 1173–1178. [Google Scholar] [CrossRef] [PubMed]
- Barcia, C.; Ros, C.M.; Annese, V.; Gomez, A.; Ros-Bernal, F.; Aguado-Yera, D.; Martinez-Pagan, M.E.; de Pablos, V.; Fernandez-Villalba, E.; Herrero, M.T. IFN-gamma signaling, with the synergistic contribution of TNF-alpha, mediates cell specific microglial and astroglial activation in experimental models of Parkinson’s disease. Cell Death Dis. 2011, 2, e142. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Caiazzo, M.; Dell’Anno, M.T.; Dvoretskova, E.; Lazarevic, D.; Taverna, S.; Leo, D.; Sotnikova, T.D.; Menegon, A.; Roncaglia, P.; Colciago, G.; et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 2011, 476, 224–227. [Google Scholar] [CrossRef]
- Pfisterer, U.; Kirkeby, A.; Torper, O.; Wood, J.; Nelander, J.; Dufour, A.; Bjorklund, A.; Lindvall, O.; Jakobsson, J.; Parmar, M. Direct conversion of human fibroblasts to dopaminergic neurons. Proc. Natl. Acad. Sci. USA 2011, 108, 10343–10348. [Google Scholar] [CrossRef] [Green Version]
- Heinrich, C.; Blum, R.; Gascon, S.; Masserdotti, G.; Tripathi, P.; Sanchez, R.; Tiedt, S.; Schroeder, T.; Gotz, M.; Berninger, B. Directing astroglia from the cerebral cortex into subtype specific functional neurons. PLoS Biol. 2010, 8, e1000373. [Google Scholar] [CrossRef] [Green Version]
- Di Val Cervo, P.R.; Romanov, R.A.; Spigolon, G.; Masini, D.; Martin-Montanez, E.; Toledo, E.M.; La Manno, G.; Feyder, M.; Pifl, C.; Ng, Y.H.; et al. Induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson’s disease model. Nat. Biotechnol. 2017, 35, 444–452. [Google Scholar] [CrossRef]
- Xu, Z.; Chu, X.; Jiang, H.; Schilling, H.; Chen, S.; Feng, J. Induced dopaminergic neurons: A new promise for Parkinson’s disease. Redox Biol. 2017, 11, 606–612. [Google Scholar] [CrossRef]
- Li, X.; Zuo, X.; Jing, J.; Ma, Y.; Wang, J.; Liu, D.; Zhu, J.; Du, X.; Xiong, L.; Du, Y.; et al. Small-Molecule-Driven Direct Reprogramming of Mouse Fibroblasts into Functional Neurons. Cell Stem Cell 2015, 17, 195–203. [Google Scholar] [CrossRef] [Green Version]
- Hu, W.; Qiu, B.; Guan, W.; Wang, Q.; Wang, M.; Li, W.; Gao, L.; Shen, L.; Huang, Y.; Xie, G.; et al. Direct Conversion of Normal and Alzheimer’s Disease Human Fibroblasts into Neuronal Cells by Small Molecules. Cell Stem Cell 2015, 17, 204–212. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mesman, S.; Smidt, M.P. Acquisition of the Midbrain Dopaminergic Neuronal Identity. Int. J. Mol. Sci. 2020, 21, 4638. [Google Scholar] [CrossRef]
- Datta, I.; Mishra, S.; Mohanty, L.; Pulikkot, S.; Joshi, P.G. Neuronal plasticity of human Wharton’s jelly mesenchymal stromal cells to the dopaminergic cell type compared with human bone marrow mesenchymal stromal cells. Cytotherapy 2011, 13, 918–932. [Google Scholar] [CrossRef] [PubMed]
- Kriks, S.; Shim, J.W.; Piao, J.; Ganat, Y.M.; Wakeman, D.R.; Xie, Z.; Carrillo-Reid, L.; Auyeung, G.; Antonacci, C.; Buch, A.; et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature 2011, 480, 547–551. [Google Scholar] [CrossRef] [PubMed]
- Trzaska, K.A.; Kuzhikandathil, E.V.; Rameshwar, P. Specification of a dopaminergic phenotype from adult human mesenchymal stem cells. Stem Cells 2007, 25, 2797–2808. [Google Scholar] [CrossRef] [PubMed]
- Brodski, C.; Blaess, S.; Partanen, J.; Prakash, N. Crosstalk of Intercellular Signaling Pathways in the Generation of Midbrain Dopaminergic Neurons In Vivo and from Stem Cells. J. Dev. Biol. 2019, 7, 3. [Google Scholar] [CrossRef] [Green Version]
- Wapinski, O.L.; Vierbuchen, T.; Qu, K.; Lee, Q.Y.; Chanda, S.; Fuentes, D.R.; Giresi, P.G.; Ng, Y.H.; Marro, S.; Neff, N.F.; et al. Hierarchical mechanisms for direct reprogramming of fibroblasts to neurons. Cell 2013, 155, 621–635. [Google Scholar] [CrossRef] [Green Version]
- Andersson, E.; Tryggvason, U.; Deng, Q.; Friling, S.; Alekseenko, Z.; Robert, B.; Perlmann, T.; Ericson, J. Identification of intrinsic determinants of midbrain dopamine neurons. Cell 2006, 124, 393–405. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Flames, N.; Hobert, O. Transcriptional control of the terminal fate of monoaminergic neurons. Annu. Rev. Neurosci. 2011, 34, 153–184. [Google Scholar] [CrossRef]
- Kim, J.; Su, S.C.; Wang, H.; Cheng, A.W.; Cassady, J.P.; Lodato, M.A.; Lengner, C.J.; Chung, C.Y.; Dawlaty, M.M.; Tsai, L.H.; et al. Functional integration of dopaminergic neurons directly converted from mouse fibroblasts. Cell Stem Cell 2011, 9, 413–419. [Google Scholar] [CrossRef] [Green Version]
- Liu, X.; Li, F.; Stubblefield, E.A.; Blanchard, B.; Richards, T.L.; Larson, G.A.; He, Y.; Huang, Q.; Tan, A.C.; Zhang, D.; et al. Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells. Cell Res. 2012, 22, 321–332. [Google Scholar] [CrossRef] [PubMed]
- Addis, R.C.; Hsu, F.C.; Wright, R.L.; Dichter, M.A.; Coulter, D.A.; Gearhart, J.D. Efficient conversion of astrocytes to functional midbrain dopaminergic neurons using a single polycistronic vector. PLoS ONE 2011, 6, e28719. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yin, J.C.; Zhang, L.; Ma, N.X.; Wang, Y.; Lee, G.; Hou, X.Y.; Lei, Z.F.; Zhang, F.Y.; Dong, F.P.; Wu, G.Y.; et al. Chemical Conversion of Human Fetal Astrocytes into Neurons through Modulation of Multiple Signaling Pathways. Stem Cell Rep. 2019, 12, 488–501. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Alexanian, A.R.; Liu, Q.S.; Zhang, Z. Enhancing the efficiency of direct reprogramming of human mesenchymal stem cells into mature neuronal-like cells with the combination of small molecule modulators of chromatin modifying enzymes, SMAD signaling and cyclic adenosine monophosphate levels. Int. J. Biochem. Cell Biol. 2013, 45, 1633–1638. [Google Scholar] [CrossRef]
- Alexanian, A.R. An efficient method for generation of neural-like cells from adult human bone marrow-derived mesenchymal stem cells. Regen. Med. 2010, 5, 891–900. [Google Scholar] [CrossRef]
- Lyashenko, N.; Winter, M.; Migliorini, D.; Biechele, T.; Moon, R.T.; Hartmann, C. Differential requirement for the dual functions of beta-catenin in embryonic stem cell self-renewal and germ layer formation. Nat. Cell Biol. 2011, 13, 753–761. [Google Scholar] [CrossRef] [Green Version]
- Artavanis-Tsakonas, S.; Rand, M.D.; Lake, R.J. Notch Signaling: Cell Fate Control and Signal Integration in Development. Science 1999, 284, 770–776. [Google Scholar] [CrossRef] [Green Version]
- Kirkeby, A.; Grealish, S.; Wolf, D.A.; Nelander, J.; Wood, J.; Lundblad, M.; Lindvall, O.; Parmar, M. Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell Rep. 2012, 1, 703–714. [Google Scholar] [CrossRef] [Green Version]
- Zhang, L.; Yin, J.C.; Yeh, H.; Ma, N.X.; Lee, G.; Chen, X.A.; Wang, Y.; Lin, L.; Chen, L.; Jin, P.; et al. Small Molecules Efficiently Reprogram Human Astroglial Cells into Functional Neurons. Cell Stem Cell 2015, 17, 735–747. [Google Scholar] [CrossRef] [Green Version]
- Yu, S.; Yang, S.; Holsboer, F.; Sousa, N.; Almeida, O.F. Glucocorticoid regulation of astrocytic fate and function. PLoS ONE 2011, 6, e22419. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, Y.; Shen, J.; Ke, K.; Gu, X. Clinical potential and current progress of mesenchymal stem cells for Parkinson’s disease: A systematic review. Neurol. Sci. 2020, 41, 1051–1061. [Google Scholar] [CrossRef] [PubMed]
- Flitsch, L.J.; Laupman, K.E.; Brustle, O. Transcription Factor-Based Fate Specification and Forward Programming for Neural Regeneration. Front. Cell. Neurosci. 2020, 14, 121. [Google Scholar] [CrossRef] [PubMed]
- Qin, H.; Zhao, A.; Fu, X. Small molecules for reprogramming and transdifferentiation. Cell. Mol. Life Sci. 2017, 74, 3553–3575. [Google Scholar] [CrossRef]
- Smidt, M.P.; Burbach, J.P. How to make a mesodiencephalic dopaminergic neuron. Nat. Rev. Neurosci. 2007, 8, 21–32. [Google Scholar] [CrossRef]
- Chao, Y.X.; He, B.P.; Tay, S.S. Mesenchymal stem cell transplantation attenuates blood brain barrier damage and neuroinflammation and protects dopaminergic neurons against MPTP toxicity in the substantia nigra in a model of Parkinson’s disease. J. Neuroimmunol. 2009, 216, 39–50. [Google Scholar] [CrossRef]
- Buganim, Y.; Faddah, D.A.; Jaenisch, R. Mechanisms and models of somatic cell reprogramming. Nat. Rev. Genet. 2013, 14, 427–439. [Google Scholar] [CrossRef] [Green Version]
- Carla, P.C.; Floriana, P.; Umberto, D.P. The molecular code involved in midbrain dopaminergic neuron development and maintenance. Rend. Lincei 2008, 19, 271–290. [Google Scholar] [CrossRef]
- Nandy, S.B.; Mohanty, S.; Singh, M.; Behari, M.; Airan, B. Fibroblast Growth Factor-2 alone as an efficient inducer for differentiation of human bone marrow mesenchymal stem cells into dopaminergic neurons. J. Biomed. Sci. 2014, 21, 83. [Google Scholar] [CrossRef] [Green Version]
- Kiecker, C.; Bates, T.; Bell, E. Molecular specification of germ layers in vertebrate embryos. Cell. Mol. Life Sci. 2016, 73, 923–947. [Google Scholar] [CrossRef] [Green Version]
- Shetty, P.; Thakur, A.M.; Viswanathan, C. Dopaminergic cells, derived from a high efficiency differentiation protocol from umbilical cord derived mesenchymal stem cells, alleviate symptoms in a Parkinson’s disease rodent model. Cell Biol. Int. 2013, 37, 167–180. [Google Scholar] [CrossRef] [PubMed]
- An, L.; Tao, Q.; Wu, Y.; Wang, N.; Liu, Y.; Wang, F.; Zhang, L.; Shi, A.; Zhou, X.; Yu, S.; et al. Synthesis of SPIO Nanoparticles and the Subsequent Applications in Stem Cell Labeling for Parkinson’s Disease. Nanoscale Res. Lett. 2021, 16, 107. [Google Scholar] [CrossRef] [PubMed]
- Mendes-Pinheiro, B.; Anjo, S.I.; Manadas, B.; Da Silva, J.D.; Marote, A.; Behie, L.A.; Teixeira, F.G.; Salgado, A.J. Bone Marrow Mesenchymal Stem Cells’ Secretome Exerts Neuroprotective Effects in a Parkinson’s Disease Rat Model. Front. Bioeng. Biotechnol. 2019, 7, 294. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Elahi, F.M.; Farwell, D.G.; Nolta, J.A.; Anderson, J.D. Preclinical translation of exosomes derived from mesenchymal stem/stromal cells. Stem Cells 2020, 38, 15–21. [Google Scholar] [CrossRef] [Green Version]
- Alizadeh, R.; Bagher, Z.; Kamrava, S.K.; Falah, M.; Ghasemi Hamidabadi, H.; Eskandarian Boroujeni, M.; Mohammadi, F.; Khodaverdi, S.; Zare-Sadeghi, A.; Olya, A.; et al. Differentiation of human mesenchymal stem cells (MSC) to dopaminergic neurons: A comparison between Wharton’s Jelly and olfactory mucosa as sources of MSCs. J. Chem. Neuroanat. 2019, 96, 126–133. [Google Scholar] [CrossRef] [PubMed]
- McCoy, M.K.; Martinez, T.N.; Ruhn, K.A.; Wrage, P.C.; Keefer, E.W.; Botterman, B.R.; Tansey, K.E.; Tansey, M.G. Autologous transplants of Adipose-Derived Adult Stromal (ADAS) afford dopaminergic neuroprotection in a model of Parkinson s disease. Exp. Neurol. 2008, 210, 14–29. [Google Scholar] [CrossRef] [Green Version]
- Booth, H.D.E.; Hirst, W.D.; Wade-Martins, R. The Role of Astrocyte Dysfunction in Parkinson’s Disease Pathogenesis. Trends Neurosci. 2017, 40, 358–370. [Google Scholar] [CrossRef] [Green Version]
- Xiang, Z.; Xu, L.; Liu, M.; Wang, Q.; Li, W.; Lei, W.; Chen, G. Lineage tracing of direct astrocyte-to-neuron conversion in the mouse cortex. Neural Regen. Res. 2021, 16, 750–756. [Google Scholar] [CrossRef]
- Wu, Z.; Parry, M.; Hou, X.Y.; Liu, M.H.; Wang, H.; Cain, R.; Pei, Z.F.; Chen, Y.C.; Guo, Z.Y.; Abhijeet, S.; et al. Gene therapy conversion of striatal astrocytes into GABAergic neurons in mouse models of Huntington’s disease. Nat. Commun. 2020, 11, 1105. [Google Scholar] [CrossRef]
- Qian, H.; Kang, X.; Hu, J.; Zhang, D.; Liang, Z.; Meng, F.; Zhang, X.; Xue, Y.; Maimon, R.; Dowdy, S.F.; et al. Reversing a model of Parkinson’s disease with in situ converted nigral neurons. Nature 2020, 582, 550–556. [Google Scholar] [CrossRef]
- Wang, L.L.; Serrano, C.; Zhong, X.; Ma, S.; Zou, Y.; Zhang, C.L. Revisiting astrocyte to neuron conversion with lineage tracing in vivo. Cell 2021, 184, 5465–5481.e16. [Google Scholar] [CrossRef] [PubMed]
- Barker, R.A. Developing stem cell therapies for Parkinson’s disease: Waiting until the time is right. Cell Stem Cell 2014, 15, 539–542. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cooper, O.; Hargus, G.; Deleidi, M.; Blak, A.; Osborn, T.; Marlow, E.; Lee, K.; Levy, A.; Perez-Torres, E.; Yow, A.; et al. Differentiation of human ES and Parkinson’s disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid. Mol. Cell Neurosci. 2010, 45, 258–266. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Soldner, F.; Hockemeyer, D.; Beard, C.; Gao, Q.; Bell, G.W.; Cook, E.G.; Hargus, G.; Blak, A.; Cooper, O.; Mitalipova, M.; et al. Parkinson’s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009, 136, 964–977. [Google Scholar] [CrossRef] [Green Version]
- Sundberg, M.; Bogetofte, H.; Lawson, T.; Jansson, J.; Smith, G.; Astradsson, A.; Moore, M.; Osborn, T.; Cooper, O.; Spealman, R.; et al. Improved cell therapy protocols for Parkinson’s disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells 2013, 31, 1548–1562. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mahajani, S.; Raina, A.; Fokken, C.; Kugler, S.; Bahr, M. Homogenous generation of dopaminergic neurons from multiple hiPSC lines by transient expression of transcription factors. Cell Death Dis. 2019, 10, 898. [Google Scholar] [CrossRef]
- Friling, S.; Andersson, E.; Thompson, L.H. Efficient production of mesencephalic dopamine neurons by Lmx1a expression in embryonic stem cells. Proc. Natl. Acad. Sci. USA 2009, 106, 7613–7618. [Google Scholar] [CrossRef] [Green Version]
- Roy, N.S.; Cleren, C.; Singh, S.K.; Yang, L.; Beal, M.F.; Goldman, S.A. Functional engraftment of human ES cell–derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat. Med. 2006, 12, 1259–1268. [Google Scholar] [CrossRef]
- Zhang, L.X.; Yan, X.T.; An, L.; Wang, M.J.; Xu, X.; Ma, Z.L.; Nie, M.T.; Du, F.Z.; Zhang, J.Z.; Yu, S. Novel pneumatically assisted atomization device for living cell delivery: Application of sprayed mesenchymal stem cells for skin regeneration. Bio-Des. Manuf. 2021, 144, 13. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wang, N.; Ji, X.; Wu, Y.; Zhou, S.; Peng, H.; Wang, J.; Yu, S.; Zhang, J. The Different Molecular Code in Generation of Dopaminergic Neurons from Astrocytes and Mesenchymal Stem Cells. Int. J. Mol. Sci. 2021, 22, 12141. https://doi.org/10.3390/ijms222212141
Wang N, Ji X, Wu Y, Zhou S, Peng H, Wang J, Yu S, Zhang J. The Different Molecular Code in Generation of Dopaminergic Neurons from Astrocytes and Mesenchymal Stem Cells. International Journal of Molecular Sciences. 2021; 22(22):12141. https://doi.org/10.3390/ijms222212141
Chicago/Turabian StyleWang, Nana, Xingrui Ji, Yue Wu, Shaocong Zhou, Huiyu Peng, Jingwen Wang, Shuang Yu, and Jingzhong Zhang. 2021. "The Different Molecular Code in Generation of Dopaminergic Neurons from Astrocytes and Mesenchymal Stem Cells" International Journal of Molecular Sciences 22, no. 22: 12141. https://doi.org/10.3390/ijms222212141